Filing Details
- Accession Number:
- 0001209191-18-033652
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-05-29 06:17:57
- Reporting Period:
- 2018-05-23
- Accepted Time:
- 2018-05-29 06:17:57
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1439222 | Agios Pharmaceuticals Inc | AGIO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1578200 | P David Schenkein | C/O Agios Pharmaceuticals, Inc. 88 Sidney Street Cambridge MA 02139 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-05-23 | 49,374 | $0.30 | 49,374 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-05-23 | 39,774 | $90.11 | 9,600 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-05-23 | 9,301 | $91.60 | 299 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-05-23 | 299 | $92.03 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock option (right to buy) | Disposition | 2018-05-23 | 49,374 | $0.00 | 49,374 | $0.30 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
16,193 | 2019-08-12 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 271,772 | Indirect | See footnote |
Common Stock | 79,082 | Indirect | See footnote |
Footnotes
- This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $90.00 to $90.99. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $91.01 to $91.99. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $92.01 to $92.04. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
- Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
- This option was granted on August 13, 2009. The option vested as to 50% of the underlying shares upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and as to the remaining 50% of the underlying shares in equal monthly installments through June 3, 2013.